Skip to main content

Published locations for FDA approves ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria

User login

  • Reset your password
  • /content/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal-hemoglobinuria
  • /familypracticenews/article/191740/anemia/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal
  • /hematologynews/article/191740/anemia/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal
  • /internalmedicinenews/article/191740/anemia/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal
  • /hematology-oncology/article/191740/anemia/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal
  • /internalmedicine/article/191740/anemia/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal
  • /familymedicine/article/191740/anemia/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal